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BACKGROUND: Peripheral intravenous catheter (PIVC) 
use in health care is common worldwide. Failure of 
PIVCs is also common, resulting in premature removal 
and replacement.  
OBJECTIVE: To investigate the 
characteristics, management practices, and 
outcomes of PIVCs internationally.  
DESIGN: Cross-sectional study. 
 
SETTING/PATIENTS: Hospitalized patients from 
rural, regional, and metropolitan areas internationally.  
MEASUREMENTS: Hospital, device, and inserter 
characteristics were collected along with assessment of 
the catheter insertion site. PIVC use in different 
geographic regions was compared.  
RESULTS: We reviewed 40,620 PIVCs in 51 countries. 
PIVCs were used primarily for intravenous medication (n  
= 28,571, 70%) and predominantly inserted in general 
wards (n = 22,167, 55%). Two-thirds of all devices were 
 
 
 
placed in non-recommended sites such as the hand, wrist, 
or antecubital veins. Nurses inserted most PIVCs (n = 
28,575, 71%); although there was wide regional variation 
(26% to 97%). The prevalence of idle PIVCs was 14% (n  
= 5,796). Overall, 10% (n = 4,204) of PIVCs were painful 
to the patient or otherwise symptomatic of phlebitis; a 
further 10% (n = 3,879) had signs of PIVC malfunction; 
and 21% of PIVC dressings were suboptimal (n = 8,507). 
Over one-third of PIVCs (n = 14,787, 36%) had no 
documented daily site assessment and half (n = 19,768, 
49%) had no documented date and time of insertion. 
 
CONCLUSIONS: In this study, we found that many 
PIVCs were placed in areas of "exion, were symptomatic 
or idle, had suboptimal dressings, or lacked adequate 
documentation. This suggests inconsistency between 
recommended management guidelines for PIVCs and 
current practice. Journal of Hospital Medicine. May 30, 
2018. doi: 10.12788/jhm.3039 © 2018 Society of 
Hospital Medicine 
 
 
The  majority  of  hospitalized  patients  worldwide  have at  
least  one  peripheral  intravenous  catheter  (PIVC),1 making  PIVC  
insertion  one  of  the  most  common clinical  procedures.  In  the  
United  States,  physicians, advanced  practitioners,  and  nurses  
insert  over  300  million  of  
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these devices in hospitalized patients annually.2 Despite 
their prevalence, PIVCs are associated with high rates of 
compli-cations, including insertion dif!culty, phlebitis, 
in!ltration, oc-clusion, dislodgment, and catheter-associated 
bloodstream infection (CABSI), known to increase morbidity 
and mortality risk.2-9 Up to 90% of PIVCs are prematurely 
removed owing to failure before planned replacement or 
before intravenous (IV) therapy completion.3-6,10-12  
PIVC complication and failure commonly triggers insertion of 
a replacement device and can entail signi!cant costs.2-4 One 
example is PIVC-related CABSI, where treatment costs have 
been estimated to be between US$35,000 and US$56,000 per 
patient.6,13 Another important consideration is the pain and 
anxiety experienced by patients who need a replacement de-
vice, particularly those with dif!cult vascular access, who may 
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require multiple cannulation attempts to replace a PIVC.12,14-
16 In developing nations, serious adverse events related to 
PIVCs are even more concerning, because hospital 
acquired infec-tion rates and associated mortality are nearly 
20 times greater than in developed nations.17  
A number of evidence-based interventions have been sug-
gested to reduce PIVC failure rates. In addition to optimal hand 
hygiene when inserting or accessing a PIVC to prevent 
infection,18 recommended interventions include placement of the 
PIVC in an area of non-"exion such as the forearm to pro-vide 
stability for the device and to reduce patient discomfort, 
securing the PIVC to reduce movement of the catheter at the 
insertion site and within the blood vessel, and use of occlusive 
dressings that reduce the risk of external contamination of the 
PIVC site.11,19,20 Best practice guidelines also recommend the 
prompt removal of devices that are symptomatic (when phle-
bitis or other complications are suspected) and when the cath-
eter is no longer required.21,22  
Recent evidence has demonstrated that catheter size can 
have an impact on device survival rates. In adults, large-bore 
catheters of 18 gauge (G) or higher were found to have an in-
creased rate of thrombosis, and smaller-bore catheters of 22G 
or lower (in adults) were found to have higher rates of dislodg-
ment and occlusion/in!ltration. The catheter size recommend-ed 
for adults based on the latest evidence for most clinical 
applications is 20G.3,20,23,24 In addition, the documentation of 
insertion, maintenance, and removal of PIVCs in the medical 
record is a requirement in most healthcare facilities worldwide 
and is recommended by best practice guidelines; however, ad-
herence remains a challenge.1,19  
The concerning prevalence of PIVC-related complications 
and the lack of comparative data internationally on organiza-
tional compliance with best practice guidelines formed the 
rationale for this study. Our study aim was to describe the in-
sertion characteristics, management practices, and 
outcomes of PIVCs internationally and to compare these 
variables to rec-ommended best practice. 
 
MATERIALS AND METHODS 
 
Study Design and Participants  
In this international cross-sectional study, we recruited hospi-
tals through professional networks, including vascular access, 
infection prevention, safety and quality, nursing, and hospital 
associations (Appendix 2). Healthcare organizations, govern-
ment health departments, and intravascular device suppliers 
were informed of the study and requested to further dissem-
inate information through their networks. A study website was 
developed,25 and social media outlets, including Twitter®, 
LinkedIn®, and Facebook®, were used to promote the study.  
Approval was granted by the Grif!th University Human 
Research Ethics Committee in Australia (reference number 
NRS/34/13/HREC). In addition, evidence of study site and local 
institutional review board/ethics committee approval was re-
quired prior to study commencement. Each participating site 
agreed to follow the study protocol and signed an authorship 
 
 
 
agreement form. No !nancial support was provided to any site. 
Hospitalized adult and pediatric patients with a PIVC in situ on the 
day of the study were eligible for inclusion. Sample size was 
determined by local capacity. Hospitals were encouraged to audit 
their entire institution if possible; however, data were accepted from 
as little as one ward. Data collectors comprised nurses and doctors 
with experience in PIVC assessment. They were briefed on the 
study protocol and data collection forms by the local site 
coordinator, and they were supported by an overall global 
coordinator. Clinicians assessed the PIVC inser-tion site and 
accessed hospital records to collect data related to PIVC insertion, 
concurrent medications, and IV "uid orders. Further  clari!cation  of  
data  was  obtained  if  necessary  by  the clinicians  from  the  
patients  and  treating  staff.  No  identi!able 
 
patient information was collected. 
 
Data Collection  
To assess whether clinical facilities were following best practice 
recommendations, the study team developed three data col-
lection forms to collect information regarding site characteris-
tics (site questionnaire), track participant recruitment (screen-
ing log), and collect data regarding PIVC characteristics and 
management practices (case report form [CRF]). All forms were 
internally and externally validated following a pilot study in-
volving 14 sites in 13 countries.1  
The CRF included variables used to assess best practice 
in-terventions, such as catheter insertion characteristics 
(date and time, reason, location, profession of inserter, 
anatomical site of placement), catheter type (gauge, brand, 
and product), in-sertion site assessment (adverse 
symptoms, dressing type and integrity), and information 
related to the IV therapy (types of IV "uids and medications, 
"ushing solutions). Idle PIVCs were de!ned as not being 
used for blood sampling or IV therapy in the preceding 24 h.  
Data collection forms were translated into 15 languages by 
professional translators and back-translated for validity. Trans-
lation of some languages included additional rigor. For exam-
ple, Spanish-speaking members from the Spanish mainland as 
well as from South America were employed so that appropri-ate 
synonyms were used to capture local terms and practice. Three 
options were provided for data entry: directly into a pur-pose-
developed electronic database (Lime Survey® Project, 
Hamburg, Germany); on paper, then transcribed into the sur-
vey database at a later time by the hospital site; or paper entry 
then sent (via email or post) to the coordinating center for data 
entry. Once cleaned and collated, all data were provided to 
each participating hospital to con!rm accuracy and for site use 
in local quality improvement processes. Data were collected 
between June 1, 2014 and July 31, 2015. 
 
Statistical Analysis  
All data management was undertaken using SAS statistical 
software (SAS Institute Inc., Cary NC, USA). Results are pre-
sented for eight geographical regions using descriptive statis-
tics (frequencies, percentages, and 95% CIs) for the variables 
of interest. To assess trends in catheter dwell time and rates of 
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TABLE.  Demographics and Characteristics by Geographical Region  
 
     Geographic Regions (n, %)       
          
 Africa Asia Australia / New Zealand Europe Middle East North America South America South Paci!c Total 
 2813 (7) 6428 (16) 5855 (14) 17223 (42) 529 (1) 5258 (13) 2384 (6) 130 (1) 40620 (100) 
            
Number of Hospitals, n (%) 49 (12) 30 (7) 82 (20) 150 (37) 6 (2) 56 (14) 32 (8) 1 (1) 406 (100) 
Age, Median (IQR), yrs. 45 (27–64) 50 (32–66) 63 (43–77) 64 (43–77) 44 (26–65) 63 (47–75) 46 (22–64) 46 (22–64) 59 (37–74) 
Male gender, n (%) 1231 (45) 3315 (52) 3036 (52) 8889 (52) 279 (53) 2543 (48) 1188 (50) 69 (53) 20550 (51) 
               
Primary insertion area n (%)               
General ward / clinic 1432 (51) 5203 (81) 1980 (34) 9596 (57) 304 (58) 2303 (44) 1266 (54) 83 (64) 22167 (55) 
Emergency department 374 (13) 317 (5) 1639 (28) 2958 (17) 134 (25) 1375 (26) 576 (24) 15 (12) 7388 (18) 
Primary inserter, n (%)               
Nurse 1947 (70) 5416 (84) 1518 (26) 13524 (79) 506 (96) 3606 (69) 1932 (81) 126 (97) 28575 (71) 
Doctor 688 (25) 684 (11) 2579 (45) 1575 (9) 7 (1) 95 (2) 116 (5) 1 (1) 5745 (14) 
Primary reason for PIVC, n (%)               
IV medications 2215 (79) 4145 (65) 3677 (63) 12751 (74) 400 (76) 3418 (65) 1873 (79) 92 (71) 28571 (70) 
IV !uids 427 (15) 1747 (27) 1133 (19) 2327 (14) 85 (16) 1005 (19) 345 (15) 24 (19) 7093 (18) 
Primary clinical specialty, n (%)               
General surgery 1014 (36) 2017 (31) 2740 (47) 6579 (38) 257 (47) 1993 (38) 960 (40) 56 (43) 15616 (38) 
General medicine 1025 (36) 3041 (47) 1690 (29) 7340 (43) 165 (31) 1591 (30) 528 (22) 68 (52) 15448 (38) 
               
Primary PIVC size, n (%)               
Medium (20–22 gauge) 2042 (73) 3307 (51) 4060 (69) 12088 (70) 418 (79) 3887 (74) 1327 (56) 63 (49) 27192 (67) 
Primary insertion site, n (%)               
Hand 1265 (45) 2993 (47) 1879 (32) 5017 (29) 295 (56) 1166 (22) 603 (25) 47 (36) 13265 (33) 
Forearm 798 (28) 1691 (26) 1362 (23) 5863 (34) 113 (21) 1937 (37) 863 (36) 48 (37) 12675 (31) 
Primary PIVC dressing, n (%)               
Transparent Film 2079 (74) 5563 (87) 5677 (97) 11002 (64) 403 (76) 5188 (99) 1582 (66) 102 (78) 31596 (78) 
               
 
 
phlebitis, Poisson regression was used. All analyses were un-
dertaken using the R language for statistical analysis (R Core 
Team, Vienna, Austria). The (STROBE (Strengthening the Re-
porting of Observational Studies in Epidemiology statement) 
guidelines for cross-sectional studies were followed, and re-
sults are presented according to these recommendations.26 
 
RESULTS  
Of the 415 hospitals that participated in this study, 406 had pa-
tients with PIVCs on the day of the study (the others being small 
rural centers). Thus, a total of 40,620 PIVCs in 38,161 patients 
from 406 hospitals in 51 countries were assessed, with no more 
than 5% missing data for any CRF question. There were 2459 
patients (6.1%) with two or more PIVCs concurrently in situ. The 
median patient age was 59 y (interquartile range [IQR], 37–74 
y), and just over half were male (n = 20,550, 51%). Hospital size 
ranged from fewer than 10 beds to over 1,000 beds, and hospi-
tals were located in rural, regional, and metropolitan districts. 
The majority of countries (n = 31, 61%) contributed multiple 
sites, the highest being Australia with 79 hospitals. Countries 
with the most PIVCs studied were Spain (n = 5,553, 14%) and 
the United States (n = 5,048, 12%).  
General surgical (n = 15,616, 39%) and medical (n = 15,448, 
38%) patients represented most of the population observed. 
PIVCs were inserted primarily in general wards or clinics (n = 
22,167, 55%) or in emergency departments (n = 7,388, 18%; 
Table) and for the administration of IV medication (n = 28,571, 
70%) and IV "uids (n = 7,093, 18%; Table). 
 
 
Globally, nurses were the primary PIVC inserters (n = 28,575, 
71%); however, Australia/New Zealand had only 26% (n = 
1,518) of PIVCs inserted by this group (Table). Only about one-
third of PIVCs were placed in an area of non-"exion (forearm, n 
= 12,675, 31%, Table) the majority (n = 27,856, 69%) were 
placed in non-recommended anatomical sites (Figure 1). Most 
PIVCs were placed in the hand (n = 13,265, 32.7%) followed by 
the antecubital veins (n = 6176, 15.2%) and the wrist (n = 5,465, 
13.5%). Site selection varied widely across the regions; 29% (n  
= 1686) of PIVCs in Australia/New Zealand were inserted 
into the antecubital veins, twice the study group average. 
Over half of the PIVCs inserted in the Middle East were 
placed in the hand (n = 295, 56%). This region also had the 
highest preva-lence of devices placed in nonrecommended 
sites (n = 416, 79%; Figure 1).  
The majority of PIVCs (n = 27,192, 67%; Table) were of 
rec-ommended size (20–22G); however, some devices were 
ob-served to be large (14–18G; n = 6,802, 17%) or small 
(24-26g; n = 4,869, 12%) in adults. In Asia, 41% (n = 2,617) 
of devices inserted were 24-26G, more than three times the 
global rate. Half of all devices in Asia (n = 3,077, 48%) and 
the South Paci!c (n = 67, 52%) were of a size not 
recommended for routine IV therapy (Figure 2).  
The primary dressing material used was a transparent dress-ing 
(n = 31,596, 77.8%) (Table); however, nearly 1 in 5 dressings used 
had either nonsterile tape alone (n = 5,169, 13%; Appen-dix 4), or a 
sterile gauze and tape (n = 2,592, 6%; Appendix 4.1). We found a 
wide variation in the use of nonsterile tape, 
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 Non-recommended PIVC site                                  
          Reference line = overall rate (69.6%)      
  Events Total                            Rate (95%Cl) 
                                   
 Africa 2013  2813                           0.72 [0.70, 0.73] 
 Asia 4729  6428                           0.74 [0.72, 0.75] 
 
Australia and New Zealand 4474 
 
5855 
                            
0.76 [0.75, 0.78]                             
 
Europe 11313 
 
17223 
                            
0.66 [0.65, 0.66]                             
 
Middle East 416 
 
529 
                            
0.79 [0.75, 0.82]                             
 
North America 3319 
 
5258 
                            
0.63 [0.62, 0.64]                             
 
South America 1510 
 
23384 
                            
0.63 [0.61, 0.65] 
                              
                            
 
South Paci!c 82 
 
130 
                            
0.63 [0.55, 0.71]                             
                                     
                                   
                                     
  0.2 0.3 0.4 0.5 0.6   0.7  0.8   0.9 1  
            Rate                    
                                  
FIG 1. Non-Recommended Peripheral Intravenous Catheter site                                   
 
 
including 1 in every 3 devices in South America dressed with 
nonsterile tape (n = 714, 30%) and a larger proportion in Africa 
(n = 543, 19%) and Europe (n = 3,056, 18%). Nonsterile tape 
was rarely used in North America and Australia/New Zealand. 
Although most PIVC dressings were clean, dry, and intact (n = 
31,786, 79%; Table), one-!fth overall were compromised (moist, 
soiled, and/or lifting off the skin). Compromised dressings (Ap-
pendix 4.2) were more prevalent in Australia/New Zealand (n = 
1,448; 25%) and in Africa (n = 707, 25%) than elsewhere.  
Ten percent of PIVCs (n = 4,204) had signs and/or symptoms 
suggestive of phlebitis (characterized by pain, redness and/ or 
swelling at the insertion site; Appendix 4.3). The highest 
prevalence of phlebitis occurred in Asia (n = 1,021, 16%), Africa 
(n = 360, 13%), and South America (n = 284, 12%). Pain and/ or 
redness were the most common phlebitis symptoms. We found 
no association between dwell time of PIVCs and phle-bitis rates 
(P = .085). Phlebitis rates were 12% (Days 1-3; n = 15,625), 
16% (Days 4-7; n = 3,348), 10% (Days 8-21; n = 457), and 13% 
(Day21+; n = 174). Nearly 10% (n = 3,879) of catheters were 
observed to have signs of malfunction such as blood in the 
infusion tubing, leaking at the insertion site, or dislodg-ment 
(Appendix 4.4).  
We observed 14% (n = 5,796) of PIVCs to be idle (Appendix 
4.5), de!ned as not used in the preceding 24 h. Nearly one-
fourth of all devices in North America (n = 1,230, 23%) and 
Australia/New Zealand (n = 1,335, 23%) were idle. PIVC doc-
umentation in hospital records was also poor, nearly half of all 
PIVCs (n = 19,768, 49%) had no documented date and time of 
 
 
insertion. The poorest compliance was in Australia/New Zea-
land (n = 3,428, 59%; Appendix 4.6). We also observed that 1 
in 10 PIVCs had no documentation regarding who inserted the 
PIVC (n = 3,905). Thirty-six percent of PIVCs (n = 14,787) had 
no documented assessment of the PIVC site on the day of 
review (Appendix 4.7), including over half of all PIVCs in Asia (n  
= 3,364, 52%). Overall, the median dwell at the time of 
assess-ment for PIVCs with insertion date/time documented 
was 1.5 d (IQR, 1.0–2.5 d). 
 
DISCUSSION  
This international assessment of more than 40,000 PIVCs in 51 
countries provides great insight into device characteristics and 
variation in management practices. Predominantly, PIVCs were 
inserted by nurses in the general ward environment for IV med-
ication. One in ten PIVCs had at least one symptom of phlebi-
tis, one in ten were dysfunctional, one in !ve PIVC dressings 
were compromised, and one in six PIVCs had not been used in 
the preceding 24 h. Nearly half of the PIVCs audited had the 
insertion date and time missing.  
Regional variation was found in the professions inserting 
PIVCs, as well as in anatomical placement. In Australia/New 
Zealand, the proportion of nurses inserting PIVCs was much 
lower than the study group average (26% vs 71%). Because 
these countries contributed a substantial number of hospitals to 
the study, this seems a representative !nding and suggests a 
need for education targeted at nurses for PIVC insertion in this 
region. The veins in the forearm are recommended as 
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 Non-recommended PIVC size                                      
                 Reference line = overall rate (31.7%)      
  Events Total                                Rate (95%Cl) 
                                          
 
Africa 705 
 
2813 
                              
0.25 [0.23, 0.27] 
                                     
 
Asia 3077 
 
6428 
                              
0.48 [0.47, 0.49] 
                                     
 
Australia and New Zealand 1317 
 
5855 
                              
0.22 [0.21, 0.24]                                      
                                     
 
Europe 4609 
 
17223 
                              
0.27 [0.26, 0.27]                                      
                                     
 
Middle East 102 
 
529 
                              
0.19 [0.16, 23] 
 
                                      
 
North America 1318 
 
5258 
                              
0.25 [0.24, 0.26]                                      
                                     
 
South America 895 
 
2384 
                              
0.38 [0.36, 0.39] 
                                     
 
South Paci!c 67 
 
130 
                              
0.52 [0.43, 0.60] 
                                     
                                       
                                            
  0 0.1 0.2    0.3 0.4    0.5      0.6  0.7 0.8  
                 Rate                 
                                         
FIG 2. Non-Recommended Peripheral Intravenous Catheter size                                          
 
 
optimal for PIVC insertion in adults, rather than areas of high 
"exion, because the forearm provides a wide surface area to 
secure and dress PIVCs. Forearm placement can reduce pain 
during catheter dwell as well as decrease the risk of accidental 
removal or occlusion.3,19,27 We found only one-third of PIVCs 
were placed in the forearm, with most placed in the hand, an-
tecubital veins, or wrist. This highlights an inconsistency with 
published recommendations and suggests that additional 
training and technology are required so that staff can better 
identify and insert PIVCs in the forearm for other than very 
short-term (procedural) PIVCp;s.19  
Phlebitis triggering PIVC failure remains a global clinical 
challenge with numerous phlebitis de!nitions and varied as-
sessment techniques.10 The prevalence of phlebitis has been 
dif!cult to approximate with varying estimates and de!nitions in 
the literature; however, it remains a key predictor of PIVC fail-
ure.6,10 Identi!cation of this complication and prompt removal of 
the device is critical for patient comfort and reducing CABSI 
risk.5,28 The overall prevalence of phlebitis signs or symptoms 
(de!ned in this study as having one or more signs of redness, 
swelling, or pain surrounding the insertion site) was just over 
10%, with pain and/or redness being most prevalent. These 
compromised PIVCs had not been removed as is recommend-
ed for such complications.19,28 Considering that our study was a 
snapshot at only one time point, the per-catheter incidence of 
phlebitis would be even higher; interestingly, among PIVCs with 
a documented insertion date and time, we observed that dwell 
time did not in"uence phlebitis rates. 
 
 
Another concern is that nearly 10% (n = 3,879) of PIVCs 
were malfunctioning (eg, leaking) but were still in place. To 
bring these problems into context, around 2 billion PIVCs 
are used annually worldwide; as a consequence, millions of 
patients suffer from painful or malfunctioning PIVCs staff 
had not re-sponded.1,29 The placement of large-bore 
catheters, and small-er-gauge ones in adults, is known to 
increase the incidence of malfunction that leads to failure. 
There are a number of sound clinical reasons for the use of 
large-bore (eg, resuscitation and rapid "uid replacement) or 
small-bore (eg, dif!cult venous access with small super!cial 
veins only visible and palpable) catheters. However, it would 
be expected that only a small pro-portion of patients would 
require these devices, and not one in three devices as we 
identi!ed. This !nding suggests that some PIVCs were 
inappropriate in size for general IV therapy and may re"ect 
antiquated hospital policies for some clinical cohorts.30,31  
Overall, transparent dressings were used to cover the PIVC, 
but a number of patients were observed to have a sterile gauze 
and tape dressing (n = 2,592, 6%). Although the latter is less 
common, both dressing approaches are recommended in clin-
ical practice guidelines because there is a lack of high-quality 
evidence regarding which is superior.21,22,32 Of concern was the 
use of nonsterile tape to dress the PIVC (n = 5,169, 12.7%). We 
found the prevalence of nonsterile tape use to be higher in 
lower-resourced countries in South America (n = 714, 30%), Af-
rica (n = 543, 19%) and Europe (n = 3,056, 18%) and this was 
likely related to institutional cost reduction practices. 
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This !nding illustrates an important issue regarding proper 
PIVC care and management practices in developing nations. It 
is widely known that access to safe health care in lower-re-
sourced nations is challenging and that rates of mortality relat-
ed to healthcare-associated infections are much higher. Thus, 
the differences we found in PIVC management practices in 
these countries are not surprising.33,34 International health net-
works such as the Infection Control Africa Network, the Inter-
national Federation of Infection Control, and the Centers for 
Disease Control and Prevention can have great in"uence on 
ministries of health and clinicians in these countries to devel-op 
coordinated efforts for safe and sustainable IV practices to 
reduce the burden of hospital-acquired infections and related 
morbidity and mortality.  
We found that 14% of all PIVCs had no documented IV med-
ication or IV "uid administered in the previous 24 h, strongly 
indicating that they were no longer needed. Australia/New 
Zealand, Europe, and North America were observed to have a 
higher prevalence of idle catheters than the remaining regions. 
This suggests that an opportunity exists to develop surveillance 
systems that better identify idle devices for prompt removal to 
reduce infection risk and patient discomfort. Several random-
ized controlled trials, a Cochrane review, and clinical practice 
guidelines recommend prompt removal of PIVCs when not 
required, if there are any complications, or if the PIVC was in-
serted urgently without an aseptic insertion technique.21,28,35,36 
Idle PIVCs have been implicated in adverse patient outcomes, 
including phlebitis and CABSI.13,27  
The substantial proportion of patients with a PIVC in this 
study who had no clinical indication for a PIVC, a symptomatic 
insertion site, malfunctioning catheter, and suboptimal dress-ing 
quality suggests the need for physicians, advanced prac-
titioners, and nurses to adopt evidence-based PIVC insertion 
and maintenance bundles and supporting checklists to reduce 
the prevalence of PIVC complications.19,21,38-40 Recommend-ed 
strategies for inclusion in PIVC maintenance bundles are 
prompt removal of symptomatic and/or idle catheters, hand 
hygiene prior to accessing the catheter, regular assessment of 
the device, and replacement of suboptimal dressings.41,42 This 
approach should be implemented across all clinical specialties 
involved in PIVC insertion and care.  
Our study !ndings need to be considered within the context of 
some limitations. The cross-sectional design prevented fol-low-
up of PIVCs until removal to collect outcomes, including 
subsequent PIVC complications and/or failure, following the 
study observation. Ideally, data collection could have included 
patient-level preferences for PIVC insertion, history of PIVC use 
and/or failure, the number of PIVC insertion attempts, and the 
number of PIVCs used during that hospitalization. However, a 
cohort study of this magnitude was not feasible, particularly 
because all sites contributed staff time to complete the data 
collection. Only half of all initially registered sites eventually 
participated in the study; reasons for not participating were cit-
ed as local workload constraints and/or dif!culties in applying for 
local approvals. Although efforts to enroll hospitals world-wide 
were exhaustive, our sample was not randomly selected 
 
 
 
but relied on self-selection and so is not representative, partic-
ularly for countries that contributed only one hospital site. Cau-
tion is also required when comparing inter regional differenc-es, 
particularly developing regions, because better-resourced/ 
academic sites were possibly over represented in the sample. 
Nevertheless, PIVC variables differed signi!cantly between 
participating hospitals, suggesting that the data represent a 
reasonable re"ection of hospital variability. 
 
CONCLUSIONS  
On the basis of this international investigation, we report 
variations in the characteristics, management practices, and 
outcomes of PIVCs inserted in hospital patients from 51 coun-
tries. Many PIVCs were idle, symptomatic, had substandard 
dressings, and were inserted in suboptimal anatomical sites. 
Despite international best practice guidelines, a large number of 
patients had PIVCs that were already failing or at risk of com-
plications, including infection. A stronger focus is needed on 
compliance with PIVC insertion and management guidelines; 
better surveillance of PIVC sites; and improved assessment, 
decision-making, and documentation. 
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